Drugs / recombinant SARS-CoV-2 S-Trimer vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05716347 | Jul 2022 → Sep 2023 | COVID-19 | Binhui Biopharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant SARS-CoV-2 S-Trimer vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05716347 ↗ |
| Modality | Vaccine | “recombinant SARS-CoV-2 S-Trimer vaccine” NCT05716347 ↗ |